Table of Contents Author Guidelines Submit a Manuscript
Clinical Study
Multiple Sclerosis International
Volume 2012, Article ID 650462, 2 pages
http://dx.doi.org/10.1155/2012/650462
Letter to the Editor

“Calcitriol” Is Not Synonymous with “Vitamin D”

1Department of Chemistry and Chemical Engineering, Royal Military College of Canada and Department of Nutritional Sciences, University of Toronto, Toronto, ON, Canada M5S 3E2
2Neurosciences and Mental Health, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada M5G 1X8

Received 21 June 2012; Accepted 2 October 2012

Copyright © 2012 Samantha M. Kimball and Heather E. Hanwell. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Shaygannejad, M. Janghorbani, F. Ashtari, and H. Dehghan, “Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial,” Neurological Research, vol. 2012, Article ID 452541, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Vieth, “Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety,” American Journal of Clinical Nutrition, vol. 69, no. 5, pp. 842–856, 1999. View at Google Scholar · View at Scopus
  3. J. N. Hathcock, A. Shao, R. Vieth, and R. Heaney, “Risk assessment for vitamin D,” American Journal of Clinical Nutrition, vol. 85, no. 1, pp. 6–18, 2007. View at Google Scholar · View at Scopus
  4. D. M. Wingerchuk, J. Lesaux, G. P. A. Rice, M. Kremenchutzky, and G. C. Ebers, “A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 9, pp. 1294–1296, 2005. View at Publisher · View at Google Scholar · View at Scopus